Revolution Medicines partners with Iambic to use the NeuralPLexer AI platform for advancing oncology research. This collaboration aims to tackle challenging drug targets in cancer treatment. The $25M deal emphasizes the increasing role of AI in enhancing drug discovery processes, potentially benefiting countless patients globally.
💊 Revolution Medicines and Iambic Accelerate Cancer Drug Discovery with AI
